IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

HOSPIRA, INC., Plaintiff/Counterclaim Defendant, v. AMNEAL PHARMACEUTICALS LLC, Defendant/Counterclaim Plaintiff.	)	C.A. No. 15-697-RGA

AMNEAL'S NOTICE OF DEPOSITION OF HOSPIRA, INC. PURSUANT TO FED. R. CIV. P. 30(b)(6)

PLEASE TAKE NOTICE that, pursuant to Rule 30(b)(6) of the Federal Rules of Civil Procedure, Defendant Amneal Pharmaceuticals LLC ("Amneal") by its attorneys, will take the deposition upon oral examination of Plaintiff Hospira, Inc. (“Hospira”), before a court reporter, notary public, or other person authorized by law to administer oaths and take testimony. The deposition will commence at 9:00 AM EST on September 14 2016, at the offices of Sughrue Mion, PLLC, 2100 Pennsylvania Avenue, NW, Washington, DC 20037, or such other date, time, and location as may be mutually agreed to by counsel. The deposition will be recorded by stenographic means and will be videotaped. You are invited to attend and participate.

PLEASE TAKE FURTHER NOTE that, pursuant to Rule 30(b)(6), Hospira is required to designate and produce one or more knowledgeable person to testify on its behalf with respect to the matters set forth in Schedule A, attached hereto. The person(s) so designated shall be required to testify as to those matters known or reasonably available to Hospira. Amneal

DOCKET ALARM
Find authenticated court documents without watermarks at docketalarm.com.

requests that Hospira identify in writing at least ten (10) business days in advance of the deposition, the name(s) and title(s) of the person(s) who will testify on its behalf and the subject matters on which each person will testify. You are invited to attend and cross-examine.

/s/ Kelly E. Farnan
Kelly E. Farnan (#4395)
Christine D. Haynes (#4697)
Richards, Layton & Finger, P.A.
One Rodney Square
920 North King Street
Wilmington, DE 19801
(302) 651-7700
farnan@rlf.com
haynes@rlf.com
Attorneys for Defendant-Counterclaim Plaintiff Amneal Pharmaceuticals LLC

Of Counsel:
Michael R. Dzwonczyk
Azy S. Kokobi
Grant S. Shackelford
Sughrue Mion, PLLC
2100 Pennsylvania Ave., NW
Washington, DC 20037
(202) 293-7060

Dated: August 31, 2016

DOCKET ALARM
Find authenticated court documents without watermarks at docketalarm.com.

DEFINITIONS

1. "Plaintiff" and "Hospira" shall refer to Hospira, Inc., its officers, directors, employees, agents, partners, corporate parents, subsidiaries, or affiliates.

2. "Defendant" and "Amneal" shall refer to Amneal Pharmaceuticals LLC.

3. "FDA" shall refer to the U.S. Food and Drug Administration, its officers and program centers, employees, or agents.

4. "PTO" shall refer to the U.S. Patent and Trademark Office.

5. "NDA" shall refer to New Drug Application.

6. The "'158 Patent" shall mean U.S. Patent No. 8,242,158, entitled "Dexmedetomidine premix formulation" and issued on August 14, 2012.

7. The "'470 Patent" shall mean U.S. Patent No. 8,338,470, entitled "Dexmedetomidine premix formulation" and issued on December 25, 2012.

8. The "'527 Patent" shall mean U.S. Patent No. 8,445,527, entitled "Methods of treatment using a dexmedetomidine premix formulation" and issued on June 4, 2013.

9. The "'106 Patent" shall mean U.S. Patent No. 8,648,106, entitled "Dexmedetomidine premix formulation" and issued on February 11, 2014.

10. "The Precedex™ Patents" or "Patents-in-suit" shall refer collectively to the '158 Patent, the '470 Patent, the '527 Patent, and the '106 Patent.

11. "Inventors" shall mean the named inventors of the patents-in-suit.

12. "Current Litigation" shall mean the lawsuit entitled *Hospira, Inc. v. Amneal Pharmaceuticals LLC*, Civil Action No. 15:697-RGA, pending in the United States District

DOCKET ALARM Find authenticated court documents without watermarks at docketalarm.com.

Court for the District of Delaware.

13. "Dexmedetomidine" shall mean the S-enantiomer of medetomidine, as the free base or pharmaceutically acceptable salt.

14. "Precedex™" shall mean any Dexmedetomidine product sold under the PRECEDEX™ trademark, including Precedex™ Concentrate and Precedex™ Premix, marketed pursuant to NDA No. 21038 and Supplemental NDA Nos. 21038/S-020 and 21038/S-024.

15. "Amneal's Proposed ANDA product" shall mean the dexmedetomidine product described in ANDA No. 207551 and for which Amneal seeks FDA approval.

16. "The ANDA" and "Amneal's ANDA" shall refer to ANDA No. 207551 and any supplements, amendments and/or correspondence with the FDA related thereto.

17. "The NDA" or "Hospira's NDA" shall mean NDA No. 21-038.

18. "The Supplemental NDAs" shall mean, collectively, New Drug Application No. 21038 Pre-Approval Supplement S-016, New Drug Application No. 21038 Pre-Approval Supplement S-020 and/or New Drug Application No. 21038 Pre-Approval Supplement S-024.

19. "The Certification" and "Amneal's Certification" shall mean the certification submitted to the FDA by Amneal and referred to in an notice letter and detailed statement dated June 26, 2015 addressed to Plaintiff.

20. "The Notice Letter" or "Amneal's Notice Letter" shall mean the Notice of Certification Under 21 U.S.C. § 355(j)(2)(B) dated June 26, 2015, from Amneal to Hospira, including the detailed statement of the factual and legal bases for the opinions set forth therein.

21. "Prior Art" shall refer to those references that may be used to evaluate the novelty and nonobviousness of claimed subject matter in a patent application or patent and includes all

DOCKET ALARM Find authenticated court documents without watermarks at docketalarm.com.

things, patents, published applications, publications, disclosures, sales, offers for sale, prior uses or other acts or occurrences included within the meaning of 35 U.S.C. §§ 102 and 103. "Prior Art," as that term is used herein, includes both documentary sources (patents and publications from anywhere in the world) and non-documentary sources (things known, used or invented in the United States).

22. "Concerning" shall refer to relating to, referring to, describing, evidencing or constituting.

23. "Communication" shall refer to any information (in the form of facts, ideas, inquiries, or otherwise) transmitted or transferred, whether oral or written.

24. The use of the singular form of any word includes the plural and vice versa.

DOCKET ALARM Find authenticated court documents without watermarks at docketalarm.com.

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.